UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_____________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): August 10, 2020
STRATA SKIN SCIENCES, INC.
(Exact Name of Registrant Specified in Charter)
|
Delaware
|
000-51481
|
13-3986004
|
|
(State or Other
|
(Commission File
|
(I.R.S. Employer
|
|
Jurisdiction of
|
Number)
|
Identification No.)
|
|
Incorporation)
|
|
|
|
|
5 Walnut Grove Drive, Suite 140, Horsham, Pennsylvania
|
19044
|
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
|
Registrant's telephone number, including area code: 215-619-3200
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
□
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
□
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading
Symbol(s) |
Name of each exchange on which registered
|
|
Common Stock, $0.001 par value per share
|
SSKN
|
The NASDAQ Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2
of this chapter).
Emerging growth company □
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act. □
Item 2.02. Results of Operations
and Financial Condition.
On August 11, 2020, STRATA Skin Sciences, Inc. (the “Company”) issued a press release announcing its results of operations for the second fiscal quarter of 2020. The full text of such press release is
furnished as Exhibit 99.1 to this report.
The information set forth under this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be
expressly set forth by specific reference in any such filing.
Item 7.01. Regulation FD
Disclosure.
On August 11, 2020, STRATA Skin Sciences, Inc. (the “Company”) issued a press release announcing its results of operations for the second fiscal quarter of 2020 and the signing of a Settlement
Agreement and Release favorably resolving all pending and threatened lawsuits between the Company and Ra Medical Systems, Inc. The full text of such press release is furnished as Exhibit 99.1 to this report.
The information set forth under this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be
expressly set forth by specific reference in any such filing.
Item 8.01. Other Events.
Effective August 10, 2020, STRATA Skin Sciences, Inc. (the “Company”) entered into a Settlement Agreement and Release (Settlement Agreement”) with Ra Medical Systems, Inc. (“Ra Medical”), under which
the Company and Ra Medical agreed that within five business days of final execution of the Settlement Agreement, the parties are to file stipulations and/or documentation necessary to cause each of the pending lawsuits between them and with other
third-parties to be dismissed with prejudice, with each party to bear its own attorneys’ fees and costs. The pending lawsuits are: Strata Skin Sciences, Inc. and Uri Geiger v. Ra Medical Systems, Inc., civil action no. 18-21421, Court of Common Pleas,
Montgomery County, Pennsylvania; and Ra Medical Systems, Inc. v. Uri Geiger, Strata Skin Sciences, Inc., and Accelmed Growth Partners, L.P., civil action no. 3:19-cv-00920, United States District Court for the Southern District of California.
As a result of the stipulations of dismissal pursuant to the Settlement Agreement, each party releases the opposing parties from any and all claims, demands, and causes of action of any kind
whatsoever, whether known or unknown, fixed or contingent, asserted or unasserted, arising in contract, tort, statute, or operation of law, which they now have or ever had against any of the opposing parties, from the beginning of time to the date of
the Settlement Agreement, in any way arising from or relating to the allegations, claims, causes of action, allegations and/or assertions set forth in the pending lawsuits.
2
Item 9.01. Financial Statements and
Exhibits.
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
STRATA SKIN SCIENCES, INC.
|
|
|
|
|
|
|
|
|
Date: August 11, 2020
|
By:
|
/s/ Matthew C. Hill
|
|
|
|
|
Matthew C. Hill
|
|
|
|
|
Chief Financial Officer
|
|
3
EXHIBIT 10.1
SETTLEMENT AGREEMENT AND RELEASE
This Settlement Agreement and Release (“Agreement”) is dated as of August 10, 2020 (the “Effective Date”), by and between STRATA SKIN SCIENCES, INC.
(“Strata”), URI GEIGER (“Geiger”), and ACCELMED GROWTH PARTNERS, L.P. (“Accelmed”) (Strata, Geiger, and Accelmed will collectively be referred to as the “Strata Parties”), on the one hand, and RA MEDICAL SYSTEMS, INC. (“Ra Medical”), on the other
(the Strata Parties and Ra Medical will collectively be referred to as the “Settling Parties”).
RECITALS
WHEREAS, Ra Medical caused its counsel at the law firm of Wingert Grebing Brubaker & Juskie to issue a certain cease and desist demand
(the “Cease and Desist Letter”) dated August 22, 2018 to be issued to Strata;
WHEREAS, on or about August 30, 2018, in response to the Cease and Desist Letter Strata and Geiger initiated a certain declaratory action
captioned Strata Skin Sciences, Inc. and Uri Geiger v. Ra Medical Systems, Inc., civil action no. 18-21421, Court of Common Pleas, Montgomery County, Pennsylvania (the “Pennsylvania Action”), seeking, among
other things, a declaratory judgment that Strata and Geiger had no liability to Ra Medical for the assertions and potential claims set forth in the Cease and Desist Letter;
WHEREAS, on or about May 16, 2019, Ra Medical initiated a certain action captioned Ra Medical Systems, Inc.
v. Uri Geiger, Strata Skin Sciences, Inc., and Accelmed Growth Partners, L.P., civil action no. 3:19-cv-00920, United States District Court for the Southern District of California (the “California Action”) (the Pennsylvania Action and the
California Action will collectively be referred to as the “Pending Lawsuits”), asserting, among other things, that the Strata Parties were liable to Ra Medical in damages for certain activity pursuant to applicable law and a prior settlement
agreement between Ra Medical and PhotoMedex, Inc.;
WHEREAS, the Settling Parties have determined that it is in their best interest to terminate the Pending Lawsuits, with prejudice, but
without any admission of liability, except for any obligations acknowledged and/or created or excluded by this Agreement and release each other from any claims that were or could have been asserted relating to the allegations therein which have
arisen prior to the full execution of this Agreement;
NOW, THEREFORE, in consideration of the foregoing premises and the agreements, terms, and provisions contained herein, and for other good and
valuable consideration, the receipt of which is hereby acknowledged, the Settling Parties, intending to be legally bound, hereby agree as follows:
1. Incorporation
of Recitals. The foregoing recitals are incorporated and made a part of this Agreement as though set forth in full.
1
2. Releases.
(a) Release
by the Strata Parties. The Strata Parties, in consideration of the obligations set forth herein, hereby release Ra Medical, its affiliates, subsidiaries, divisions, successors,
assigns, agents, representatives, employees, officers, and directors (collectively, the “Ra Medical Releasees”) from any and all claims, demands, and causes of action of any kind whatsoever, whether known or unknown, fixed or contingent, asserted
or unasserted, arising in contract, tort, statute, or operation of law, which they now have or ever had against any of the Ra Medical Releasees, from the beginning of time to the date of the Agreement, in any way arising from or relating to the
allegations, claims, causes of action, allegations and/or assertions set forth in the Pending Lawsuits.
(b) Release
by Ra Medical. Ra Medical, in consideration of the obligations set forth herein, hereby releases the Strata Parties, and their affiliates, subsidiaries, divisions, successors, assigns, agents, representatives, employees, officers, and
directors (collectively, the “Strata Parties Releasees”) from any and all claims, demands, and causes of action of any kind whatsoever, whether known or unknown, fixed or contingent, asserted or unasserted, arising in contract, tort, statute, or
operation of law, which it now has or ever had against any of the Strata Parties Releasees, from the beginning of time to the date of the Agreement, in any way arising from or relating to the allegations, claims, causes of action, allegations
and/or assertions set forth in the Pending Lawsuits.
(a) In giving the aforementioned
releases, which include claims that might be unknown or unsuspected at present, the Settling Parties represent, warrant, and agree that they have been fully advised by their attorneys of the contents of Section 1542 of the Civil Code of the State
of California. The Settling Parties expressly waive and relinquish all rights and benefits under that section and any similar statute or common law principle of similar effect of any state or territory of the United States with respect to the
aforementioned releases. Section 1542 reads as follows:
“A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing
the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.”
3. Stipulations
of Dismissal. Within 5 business days of the complete and final execution of this Agreement, the Settling Parties shall file stipulations and/or documentation necessary to cause each of the Pending Lawsuits to be dismissed with
prejudice, with each party to bear its own attorneys’ fees and costs. Except for claims resulting from an alleged breach of this Agreement, the Settling Parties covenant and agree not to file or prosecute any claim based upon matters within the
scope of the general releases contained in Paragraph 2, supra.
4. Representation
by Counsel. All parties to this Agreement acknowledge that they (i) have been represented by counsel in negotiating this Agreement; (ii) have read, and understand all of the terms and conditions of this Agreement and the
consequences thereof; (iii) have knowingly and voluntarily entered into this Agreement; and (iv) have initiated no legal
2
proceedings related to the instant dispute other than the Pending Lawsuits. The Settling Parties hereby forever waive and relinquish any right or claim whatsoever to directly or collaterally attack the
validity of this Agreement on any grounds.
5. Interpretation
of Agreement. The Settling Parties agree that the terms of this Agreement are the product of informed negotiations, and that no presumption shall arise in the interpretation of the Agreement based upon the identity of the party that
drafted any provision hereof. Accordingly, the normal rule of construction/contract interpretation to the effect that any ambiguities are to be resolved against the drafting party will not be employed in any interpretation of this Agreement.
6. Severability.
If any provision of this Agreement or the application of any provision herein to any person or circumstance is held invalid or unenforceable only that provision shall be affected, and the remainder of this Agreement shall remain in full force and
effect.
7. Non-Waiver.
The delay or failure to enforce or seek enforcement of any right under this Agreement shall not constitute or be construed as (i) a waiver of such rights; (ii) a waiver of any remedy to enforce such rights; or (iii) acquiescence in any default.
8. Binding
Effect. This Agreement shall be binding upon and inure to the benefit of the Settling Parties and their respective affiliates, successors, and assigns. Other than the Ra Medical Releasees and the Strata Parties Releasees to the
extent set forth in Sections 2(a) and 2(b) above, there are no third‑party beneficiaries of this Agreement, and nothing contained herein shall be deemed a release, waiver or modification in any manner or to any extent whatsoever of any claims,
rights or remedies which any party to this Agreement has or may have against any person other than the parties to this Agreement, all of which claims, rights and remedies as against such non‑parties are expressly reserved.
9. Agreement
Governed By Pennsylvania Law. This Agreement shall in all respects be interpreted, enforced and governed exclusively under the internal laws of the Commonwealth of Pennsylvania (without regard to its conflict of law provisions.
10. Counterparts.
This Agreement may be signed in counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. Delivery of an executed counterpart of a signature page to this Agreement
by facsimile or electronic transmission (including in “ PDF” or similar format) shall be effective as delivery of a manually executed signature page hereto.
11. Entire
Agreement. This Agreement constitutes the complete understanding between the Settling Parties concerning all matters relating to this matter and supersedes all prior discussions, agreements and understandings, both written and oral,
between the parties with respect thereto and may not be modified other than by a written document, executed by all parties hereto.
12. Execution
of Documents to Effectuate Intent of Agreement. The Settling Parties agree to execute without further consideration any and all further documents that may be necessary to effectuate the intent of this Agreement.
3
13. Authority
to Settle. The Settling Parties warrant and represent that they have collectively all of the interest in any of the matters set forth herein and that they have the full right, power, and specific authority to enter into, execute and
consummate this Agreement.
14. Confidentiality.
The parties hereto agree to keep the terms of this Agreement and the settlement as confidential, and shall not to disclose the terms of this settlement to anyone except (a) to their attorneys, accountants and auditors, (b) as required for
governmental regulatory or compliance purposes, (c) to comply with any duly-served subpoena or discovery request in any legal proceeding, or (d) as otherwise required by law by law or a court order; provided, however, that nothing set forth in this
paragraph shall prohibit any party hereto from disclosing this Agreement to enforce its terms or from stating that the parties have amicably settled the pending disputes among them.
15. Headings. All headings and captions in this Agreement are for convenience of reference only. They shall not be deemed part of this Agreement and shall in no way define, limit, extend or describe the scope or intent of any
provisions hereof.
[Signature page follows.]
4
IN WITNESS WHEREOF, each Party has caused this Agreement to be executed as of the date first appearing above.
By: /s/ Dolev Rafaeli
Name: Dolev Rafaeli
Title: Chief Executive Officer
URI GEIGER
/s/ Uri Geiger
ACCELMED GROWTH PARTNERS, L.P.
By: /s/ Uri Geiger
Name: Uri Geiger
Title: Managing Partner
RA MEDICAL SYSTEMS, INC.
By: /s/ Daniel Horwood
Name: Daniel Horwood
Title: General Counsel
5
Exhibit 99.1
STRATA Skin Sciences Reports Second Quarter 2020 Financial Results
Recurring revenue for the second quarter of 2020 was $2.8 million, a 52.1% decrease over second quarter 2019
Total gross margins in the second quarter of 2020 was 48.7%, a 14.9% decrease over second quarter 2019
Global recurring revenue installed base totaled 806 systems at June 30, 2020
Conference call and webcast, today at 8:30 am Eastern Time
HORSHAM, Pennsylvania August 11, 2020 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA”), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing
and marketing innovative products for the treatment of dermatologic conditions, today reported financial results for the quarter ended June 30, 2020.
“While our overall second quarter revenue performance reflects the impact of the COVID-19 global pandemic, we are encouraged by the monthly improvement in our recurring revenue business, which follows the gradual
reopening of clinical practices, domestically and internationally,” said Dr. Dolev Rafaeli, Chief Executive Officer of Strata Skin Sciences.
Second Quarter Revenue and Business Highlights
|
•
|
Total revenue for the second quarter of 2020 was $4.0 million, a decrease of 47.8% over total revenues for the second quarter of 2019 as our revenue was impacted by the COVID-19 global
pandemic.
|
|
•
|
Total global XTRAC® recurring revenue in the second quarter of 2020 was $2.8 million, a decrease of 52.1% over second quarter 2019 total global XTRAC recurring revenues.
|
|
•
|
Total gross margins and recurring gross margins were 48.7% and 51.2%, respectively, a decrease of 14.9% and 19.1%, respectively, as compared to second quarter 2019.
|
|
•
|
Net loss was $1.7 million, an increase of 55.3% from a net loss of $1.1 million in the second quarter 2019.
|
|
•
|
Domestic and International recurring installed base of 789 and 17 XTRAC devices, respectively, a decrease of 33 and an increase of 1, respectively.
|
|
•
|
Cash and cash equivalents and restricted cash at June 30, 2020 was $18.6 million.
|
|
•
|
During the second quarter the Company received a $2.0 million forgivable loan under the SBA Payroll Protection Plan (the “PPP loan”) and estimates approximately 80% will be forgiven
based on current guidelines.
|
|
•
|
During the second quarter the Company also received $500 thousand in loan proceeds from the SBA under the Economic Injury Disaster Loan program (the “EIDL loan”).
|
|
•
|
Saw the publication of a physician-sponsored, peer reviewed study entitled: “308-nm Excimer Laser Plus Platelet-Rich Plasma
for Treatment of Stable Vitiligo: A Prospective, Randomized Case–Control Study” in the journal Clinical, Cosmetic and Investigational Dermatology. The randomized study, conducted at the Xian Vitiligo Specialist Hospital in China, evaluated the XTRAC Velocity 400i-308 nm excimer laser therapeutic system plus PRP in the
treatment of vitiligo patients. Results of the 60 patient trial reaffirmed that the effect of PRP combined with XTRAC on stable vitiligo is significantly better than that of PRP or 308 nm excimer laser alone.
|
|
•
|
The Company entered into a Settlement Agreement and Release with Ra Medical Systems, Inc. (“Ra Medical”), under which the Company and Ra Medical agreed to dismiss all pending lawsuits between the parties with
prejudice, each party releases the opposing parties from any and all claims, demands, and causes of action.
|
“While COVID-19 has impacted our revenue, our business has shown its resiliency and our fundamental trends are moving in the right direction as patients return to clinics. We
are seeing month to month growth in our gross domestic recurring billings from April through July of $466 thousand, $633 thousand, $749 thousand and $1.4 million, respectively, with the Midwest and Southeast at or in excess of July 2019 gross
billings. Our Patient Outreach Program has been instrumental in driving patients into our partner clinics but we do anticipate some unevenness on our path to full utilization as COVID hotspots will impact our localized partner clinics and their
ability to return to normal operations,” stated Dr. Rafaeli. “We increased our overall cash position by $3 million in the second quarter compared to the first quarter and have $11.2 million in unrestricted cash. Internationally, we are observing similar trends and anticipate international placements and equipment sales to increase as markets open up further.”
Dr. Rafaeli concluded, “We firmly believe in our strategy and in the long-term prospects of the business. Being a solution to both patients and physicians in their search for a safe and effective treatment option for
psoriasis and vitiligo resonates in the feedback we are receiving from our physician partners, and ensures XTRAC will be an important part of the recovery of our partner practices.”
* Gross Domestic Recurring Gross Billings is a non-GAAP financial measure. For more information, see “Reconciliation of Non-GAAP Measures” below.
Reported Financial Results
Revenues for the second quarter of 2020 were $4.0 million, as compared to revenues of $7.7 million for the second quarter of 2019. Recurring revenues for the second quarter of 2020 were $2.8 million, as compared to
revenues of $5.8 million for the second quarter of 2019. Equipment revenues were $1.2 million for the second quarter of 2020, as compared to $1.9 million for the second quarter of 2019. The COVID-19 pandemic has had a negative impact on the
Company’s results for the first and second quarter of 2020, and the Company expects it will have a negative impact on its revenue for as long as the pandemic continues.
Revenues for the six months ended June 30, 2020 were $10.8 million, as compared to revenues of $15.2 million for the six months ended June 30, 2019.
Gross profit for the second quarter of 2020 was $2.0 million, or 48.7% of revenues, as compared to $4.9 million, or 63.6% of revenues, for the second quarter of 2019. Gross profit on recurring revenues for the second
quarter of 2020 was $1.4 million, or 51.2% of revenues, as compared to $4.1 million, or 70.3% of revenues, for the second quarter of 2019. The decrease in gross profit is the result of lower sales due to the COVID-19 pandemic, fixed costs in
manufacturing and lower production.
Gross profit for the six months ended June 30, 2020 was $6.4 million, or 59.1% of revenues, as compared to $9.5 million, or 62.6% of revenues.
Selling and marketing costs for the second quarter of 2020 were $1.4 million, as compared to $3.0 million for the second quarter of 2019, primarily as a result of lower tradeshow costs, compensation costs, and direct
to consumer advertising costs. General and administrative costs for the second quarter of 2020 were $1.9 million, as compared to $2.7 million for the second quarter of 2019, as a result of lower legal, accounting and consulting costs. Other expense
for the second quarter of 2020 was $18 thousand, compared to $145 thousand for the second quarter of 2019 as a result of lower interest expense due to refinancing of our long-term debt in December 2019.
Sales and marketing costs for the six months ended June 30, 2020 were $4.4 million, as compared to $6.0 million for the six months ended June 30, 2019. General and administrative costs for the six months ended June
30, 2020 were $4.0 million, as compared to $5.2 million for the six months ended June 30, 2019. Other expense for the six months ended June 30, 2020 was $17 thousand, as compared to $280 thousand for the six months ended June 30, 2019.
Net (loss) for second quarter 2020 was $(1.7) million, or $(0.05) per basic and diluted common share, as compared to the net (loss) for the second quarter of 2019 of $(1.1) million, or $(0.03) per basic and diluted
common share.
Net (loss) for the six months ended June 30, 2020 was $(2.7) million, or $(0.08) per basic and diluted share, as compared to the net loss for the six months ended June 30, 2019 of $(2.4) million, or $(0.07) per basic
and diluted common share.
Reconciliation of Non-GAAP Measures
To supplement the Company’s consolidated financial statements, prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”), the Company provides certain non-GAAP
measures of financial performance, including non-GAAP adjusted EBITDA and Gross Domestic Recurring Gross Billings.
2
The Company’s reference to these non-GAAP measures should be considered in addition to results prepared under current accounting standards, but is not a substitute for, nor superior to, GAAP results. These non-GAAP
measures are provided to enhance investors' overall understanding of our current financial performance and to provide further information for comparative purposes.
Specifically, the Company believes the non-GAAP measures provide useful information to both management and investors by isolating certain expenses, gains and losses that may not be indicative of the Company’s core
operating results and business outlook. In addition, the Company believes non-GAAP measures enhance the comparability of results against prior periods. Reconciliation of the GAAP measures of net loss to non-GAAP measures included in this press
release is as follows (in thousands):
Adjusted EBITDA:
|
For the Three Months Ended
June 30,
|
For the Six Months Ended
June 30
|
|||||||||||||||
|
2020
|
2019
|
2020
|
2019
|
|||||||||||||
|
Net Loss
|
$
|
(1,680
|
)
|
$
|
(1,082
|
)
|
$
|
(2,715
|
)
|
$
|
(2,415
|
)
|
||||
|
Adjustments:
|
||||||||||||||||
|
Depreciation/amortization*
|
1,028
|
1,197
|
2,145
|
2,494
|
||||||||||||
|
Income taxes
|
47
|
(46
|
)
|
135
|
(89
|
)
|
||||||||||
|
Interest expense, net
|
18
|
145
|
17
|
280
|
||||||||||||
|
Non-GAAP EBITDA
|
(587
|
)
|
214
|
(418
|
)
|
270
|
||||||||||
|
Stock compensation
|
410
|
303
|
840
|
626
|
||||||||||||
|
Non-GAAP adjusted EBITDA
|
$
|
(177
|
)
|
$
|
517
|
$
|
422
|
$
|
896
|
|||||||
Gross Domestic Recurring Billings:
Gross domestic recurring billings represent the amount invoiced to partner clinics when treatment codes are sold to the physician. It does not include normal GAAP adjustments which are deferred revenue from prior
quarters recorded as revenue in the current quarter, the deferral of revenue from the current quarter recorded as revenue in future quarters, adjustments for co-pay and other discounts. This excludes international recurring revenues.
Gross domestic recurring billings for April, May, June and July 2020 were $466 thousand, $633 thousand, $749 thousand and $1.4 million, respectively. The total gross domestic
recurring billings for the second quarter of 2020 was $1,848,000.
The following is a reconciliation of non-GAAP gross domestic billings to recorded revenue for the second quarter of 2020 (in thousands):
|
Gross domestic recurring billings
|
$
|
1,848
|
||
|
Co-Pay adjustments
|
(86
|
)
|
||
|
Other discounts
|
(4
|
)
|
||
|
Deferred revenue from prior quarters
|
1,458
|
|||
|
Deferral of revenue to future quarters
|
(546
|
)
|
||
|
Recorded revenue
|
$
|
2,670
|
STRATA management will host a conference call with investors today, Tuesday, August 11, 2020 beginning at 8:30 am ET to review these results and answer questions. Shareholders and other interested parties may
participate in the conference call using the dial-in and webcast information as follows:
3
Conference Call Details:
|
Date:
|
Tuesday, August 11
|
|
Time:
|
8:30 am Eastern Time
|
|
Toll Free:
|
877-451-6152
|
|
International:
|
201-389-0879
|
|
Israel:
|
1 809 406 247
|
|
Passcode:
|
13707396
|
|
Webcast:
|
www.strataskinsciences.com
|
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions. Its
products include the XTRAC® excimer laser and VTRAC® lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions.
The Company’s proprietary XTRAC® excimer laser delivers a highly targeted therapeutic beam of UVB light to treat psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma, diseases, which impact over 35 million
patients in the United States alone. The technology is covered by multiple patents, including exclusive rights for patents for the delivery of treatments to vitiligo patients.
STRATA’s unique business model leverages targeted Direct to Consumer (DTC) advertising to generate awareness and utilizes its in-house call center and insurance advocacy teams to increase volume for the Company’s
partner dermatology clinics.
The XTRAC business has used this proven DTC model to grow its domestic dermatology partner network to over 789 clinics, with a worldwide installed base of over 2,000 devices. The Company is able to offer 90% of DTC
patients an introduction to physicians prescribing a reimbursable solution, using XTRAC, within a 10-mile radius of their house. The Company is a leader in dermatology in-clinic business generation for its partners.
Safe Harbor
This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans,
objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to generate the growth in its core business, the Company’s
ability to develop social media marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties and
changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions or supply chain interruptions resulting from the corona
virus and political factors or conditions affecting the Company and the medical device industry in general, as well as more specific risks and uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties,
any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise.
The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at
www.sec.gov and www.strataskinsciences.com.
Investor Contacts:
|
Matthew Hill, Chief Financial Officer
|
Chuck Padala, Managing Director
|
|
|
STRATA Skin Sciences, Inc.
|
LifeSci Advisors, LLC
|
|
|
215-619-3200
|
646-627-8390
|
|
|
ir@strataskin.com
|
chuck@lifesciadvisors.com
|
4
STRATA SKIN SCIENCES, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
|
June 30, 2020
|
December 31, 2019
|
|||||||
|
ASSETS
|
(unaudited)
|
|||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$
|
11,231
|
$
|
8,129
|
||||
|
Restricted cash
|
7,397
|
7,500
|
||||||
|
Accounts receivable, net of allowance for doubtful accounts of $256 and $184, respectively
|
1,361
|
4,386
|
||||||
|
Inventories
|
3,470
|
3,027
|
||||||
|
Prepaid expenses and other current assets
|
430
|
513
|
||||||
|
Total current assets
|
23,889
|
23,555
|
||||||
|
Property and equipment, net
|
4,999
|
5,369
|
||||||
|
Operating lease right-of-use assets, net
|
1,155
|
1,314
|
||||||
|
Intangible assets, net
|
7,050
|
7,955
|
||||||
|
Goodwill
|
8,803
|
8,803
|
||||||
|
Other assets
|
314
|
347
|
||||||
|
Total assets
|
$
|
46,210
|
$
|
47,343
|
||||
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
||||||||
|
Current liabilities:
|
||||||||
|
Note payable
|
$
|
7,275
|
$
|
7,275
|
||||
|
Current portion of long-term debt
|
799
|
-
|
||||||
|
Accounts payable
|
2,451
|
1,880
|
||||||
|
Other accrued liabilities
|
4,703
|
5,134
|
||||||
|
Current portion of operating lease liabilities
|
353
|
313
|
||||||
|
Deferred revenues
|
1,020
|
2,832
|
||||||
|
Total current liabilities
|
16,601
|
17,434
|
||||||
|
Long-term liabilities:
|
||||||||
|
Long-term debt, net
|
1,729
|
-
|
||||||
|
Deferred tax liability
|
135
|
-
|
||||||
|
Long-term operating lease liabilities, net
|
896
|
1,078
|
||||||
|
Other liabilities
|
71
|
178
|
||||||
|
Total liabilities
|
19,432
|
18,690
|
||||||
|
Commitments and contingencies
|
||||||||
|
Stockholders' equity:
|
||||||||
|
Series C Convertible Preferred Stock, $.10 par value, 10,000,000 shares authorized; - and 2,103 shares issued and outstanding at June 30, 2020 and, December 31, 2019, respectively
|
-
|
1
|
||||||
|
Common Stock, $.001 par value, 150,000,000 shares authorized; 33,754,909 and 32,932,273 shares issued and outstanding at June 30, 2020 and, December 31, 2019,
respectively
|
34
|
33
|
||||||
|
Additional paid-in capital
|
244,020
|
243,180
|
||||||
|
Accumulated deficit
|
(217,276
|
)
|
(214,561
|
)
|
||||
|
Total stockholders' equity
|
26,778
|
28,653
|
||||||
|
Total liabilities and stockholders’ equity
|
$
|
46,210
|
$
|
47,343
|
||||
5
STRATA SKIN SCIENCES, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
(unaudited)
|
For the Three Months Ended
June 30,
|
||||||||
|
2020
|
2019
|
|||||||
|
Revenues, net
|
$
|
4,030
|
$
|
7,725
|
||||
|
Cost of revenues
|
2,066
|
2,815
|
||||||
|
Gross profit
|
1,964
|
4,910
|
||||||
|
|
||||||||
|
Operating expenses:
|
||||||||
|
Engineering and product development
|
247
|
235
|
||||||
|
Selling and marketing
|
1,442
|
2,958
|
||||||
|
General and administrative
|
1,890
|
2,700
|
||||||
|
|
3,579
|
5,893
|
||||||
|
Loss from operations
|
(1,615
|
)
|
(983
|
)
|
||||
|
|
||||||||
|
Other expense, net:
|
||||||||
|
Interest expense, net
|
(18
|
)
|
(145
|
)
|
||||
|
(18
|
)
|
(145
|
)
|
|||||
|
Loss before income taxes
|
(1,633
|
)
|
(1,128
|
)
|
||||
|
Income tax (expense) benefit
|
(47
|
)
|
46
|
|||||
|
Net loss
|
$
|
(1,680
|
)
|
$
|
(1,082
|
)
|
||
|
Loss attributable to common shares
|
$
|
(1,680
|
)
|
$
|
(1,007
|
)
|
||
|
Loss attributable to Series C Convertible Preferred shares
|
-
|
$
|
(75
|
)
|
||||
|
Loss per common share:
|
||||||||
|
Basic
|
$
|
(0.05
|
)
|
$
|
(0.03
|
)
|
||
|
Diluted
|
$
|
(0.05
|
)
|
$
|
(0.03
|
)
|
||
|
Shares used in computing loss per common share:
|
||||||||
|
Basic
|
33,731,739
|
31,359,104
|
||||||
|
Diluted
|
33,731,739
|
31,359,104
|
||||||
|
Loss per Series C Convertible Preferred share basic and diluted
|
-
|
$
|
(11.94
|
)
|
||||
|
Shares used in computing loss per basic and diluted Series C Convertible Preferred shares
|
-
|
6,250
|
||||||
6
STRATA SKIN SCIENCES, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
(unaudited)
|
For the Six Months Ended
June 30,
|
||||||||
|
2020
|
2019
|
|||||||
|
Revenues, net
|
$
|
10,760
|
$
|
15,208
|
||||
|
Cost of revenues
|
4,397
|
5,689
|
||||||
|
Gross profit
|
6,363
|
9,519
|
||||||
|
|
||||||||
|
Operating expenses:
|
||||||||
|
Engineering and product development
|
539
|
539
|
||||||
|
Selling and marketing
|
4,395
|
6,024
|
||||||
|
General and administrative
|
3,992
|
5,180
|
||||||
|
|
8,926
|
11,743
|
||||||
|
Loss from operations
|
(2,563
|
)
|
(2,224
|
)
|
||||
|
|
||||||||
|
Other expense, net:
|
||||||||
|
Interest expense, net
|
(17
|
)
|
(280
|
)
|
||||
|
(17
|
)
|
(280
|
)
|
|||||
|
Loss before income taxes
|
(2,580
|
)
|
(2,504
|
)
|
||||
|
Income tax (expense) benefit
|
(135
|
)
|
89
|
|||||
|
Net loss
|
$
|
(2,715
|
)
|
$
|
(2,415
|
)
|
||
|
Loss attributable to common shares
|
$
|
(2,693
|
)
|
$
|
(2,226
|
)
|
||
|
Loss attributable to Series C Convertible Preferred shares
|
$
|
(22
|
)
|
$
|
(189
|
)
|
||
|
Loss per common share:
|
||||||||
|
Basic
|
$
|
(0.08
|
)
|
$
|
(0.07
|
)
|
||
|
Diluted
|
$
|
(0.08
|
)
|
$
|
(0.07
|
)
|
||
|
Shares used in computing loss per common share:
|
||||||||
|
Basic
|
33,448,030
|
31,033,114
|
||||||
|
Diluted
|
33,448,030
|
31,033,114
|
||||||
|
Loss per Series C Convertible Preferred share basic and diluted
|
$
|
(29.93
|
)
|
$
|
(26.66
|
)
|
||
|
Shares used in computing loss per basic and diluted Series C Convertible Preferred shares
|
740
|
7,093
|
||||||
7
STRATA SKIN SCIENCES, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands, unaudited)
|
For the Six Months Ended
June 30,
|
||||||||
|
2020
|
2019
|
|||||||
|
Cash Flows From Operating Activities:
|
||||||||
|
Net loss
|
$
|
(2,715
|
)
|
$
|
(2,415
|
)
|
||
|
Adjustments to reconcile net loss to net cash provided by operating activities:
|
||||||||
|
Depreciation and amortization
|
1,986
|
2,347
|
||||||
|
Amortization of right-of-use asset
|
159
|
147
|
||||||
|
Provision for doubtful accounts
|
72
|
2
|
||||||
|
Loss on disposal of property and equipment and lasers placed in service
|
19
|
22
|
||||||
|
Stock-based compensation
|
840
|
626
|
||||||
|
Deferred taxes
|
135
|
(89
|
)
|
|||||
|
Amortization of debt discount
|
-
|
12
|
||||||
|
Amortization of deferred financing costs
|
-
|
57
|
||||||
|
Changes in operating assets and liabilities:
|
||||||||
|
Accounts receivable
|
2,953
|
(85
|
)
|
|||||
|
Inventories
|
(443
|
)
|
(813
|
)
|
||||
|
Prepaid expenses and other assets
|
116
|
(42
|
)
|
|||||
|
Accounts payable
|
571
|
327
|
||||||
|
Other accrued liabilities
|
(431
|
)
|
248
|
|||||
|
Other liabilities
|
(107
|
)
|
(5
|
)
|
||||
|
Operating lease liabilities
|
(142
|
)
|
(126
|
)
|
||||
|
Deferred revenues
|
(1,812
|
)
|
193
|
|||||
|
Net cash provided by operating activities
|
1,201
|
406
|
||||||
|
Cash Flows From Investing Activities:
|
||||||||
|
Lasers placed-in-service
|
(730
|
)
|
(947
|
)
|
||||
|
Purchases of property and equipment
|
-
|
(5
|
)
|
|||||
|
Net cash used in investing activities
|
(730
|
)
|
(952
|
)
|
||||
|
Cash Flows From Financing Activities:
|
||||||||
|
Proceeds from note payable and long-term debt
|
2,528
|
-
|
||||||
|
Net cash provided by financing activities
|
2,528
|
-
|
||||||
|
Net increase (decrease) in cash and cash equivalents and restricted cash
|
2,999
|
(546
|
)
|
|||||
|
Cash, cash equivalents and restricted cash, beginning of period
|
15,629
|
16,487
|
||||||
|
Cash, cash equivalents and restricted cash, end of period
|
$
|
18,628
|
$
|
15,941
|
||||
|
Cash and cash equivalents
|
$
|
11,231
|
$
|
15,941
|
||||
|
Restricted cash
|
7,397
|
-
|
||||||
|
$
|
18,628
|
$
|
15,941
|
|||||
8